Analysts expect Tevogen Inc. to report revenue of 0.00 for Q3 25, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 25, came in at 0.00.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | ||||||||||||||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||||||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Tevogen Inc. to report earnings per share of -1.59 for Q4 25, against a range of -1.72 to -1.46. The most recent reported quarter, Q3 25, came in at -1.50, a 52.7% beat against the -3.17 consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -1.70 | -3.25 | -1.50 | -1.50 | - | - | - | - | - | - | - | - | |||||||||||||
| High Estimate | -1.72 | -2.43 | -2.42 | -3.01 | -1.46 | -2.48 | -2.53 | -2.44 | -2.34 | -2.90 | -2.90 | -2.93 | |||||||||||||
| Low Estimate | -1.90 | -2.59 | -2.88 | -3.33 | -1.72 | -2.98 | -2.69 | -2.94 | -2.68 | -3.42 | -3.22 | -3.45 | |||||||||||||
| Consensus Estimate | -1.81 | -2.51 | -2.65 | -3.17 | -1.59 | -2.73 | -2.61 | -2.69 | -2.51 | -3.16 | -3.06 | -3.19 |